The over-the-counter (OTC) market is experiencing a fundamental shift. It is no longer just about treating acute symptoms; it is about empowering daily wellness and continuous self-care — with consumers making more proactive choices in their everyday routines. As we move through 2026, this transformation is accelerating, driven by a consumer who is more informed and proactive than ever.
In this article, we use the term “Consumer Health” to refer to the self-care ecosystem in the pharmacy channel, which encompasses OTC/MIP medications and adjacent categories such as VMS (vitamins, minerals, and supplements).
This new dynamic of Consumer Health OTC requires the industry to look beyond the traditional shelf, integrating convenience and efficacy into formulations that keep pace with modern life.
For formulators, CDMOs, and R&D teams, this “next phase” represents both a challenge and a massive opportunity. To win, portfolios must evolve faster, moving from reactive medicine to proactive health solutions.
The New Drivers of OTC Growth for OTC Consumer Health
According to the IQVIA – Consumer Health’s Next Phase (2026) report, the engines of growth have changed. While traditional categories remain stable, the real acceleration is happening where health meets lifestyle.
VMS (Vitamins, Minerals, and Supplements)
This is the fastest-growing segment, fueled by a global focus on immunity and longevity. Consumers are looking for personalized solutions that fit seamlessly into their daily routines.
Digestive and Skin Health
The boundary between beauty and pharma is blurring. Consumers now seek clinically backed treatments for gut health and visible skin barrier repair, treated with the same rigor as pharmaceutical products.
Innovation Is Now Consumer-Led
In the past, innovation was driven primarily by active ingredient discovery. Today, the consumer is the lead architect. They are demanding:
- Clean Label: transparency in ingredient lists and a preference for recognizable, high-purity components.
- Convenience: new delivery formats like gummies, sprays, and fast-dissolving films.
- Efficacy: a demand for visible results that are backed by science, not just marketing claims.
Consumer Health OTC: Connecting Trends to the Formulator’s Needs
For the professional in the lab, translating these “consumer desires” into a stable, effective product is the real challenge. Innovation relevant to the market requires technical excellence from the start.
In a market built on trust, consistency, and safety, the technical foundation of the formulation and the choice of high-purity excipients, matters more than ever.
The choice of excipients is no longer a secondary detail; it is a strategic decision. High-performance excipients, such as the OXIPURITY® line, are the foundation for:
- Ensuring Stability: Protecting sensitive actives from degradation.
- Supporting formulation performance: contributing to solubilization and release strategies and consistency of performance, depending on the product design.
- Regulatory and quality support: helping meet requirements across markets (e.g., FDA, EMA) through robust documentation and traceability, reducing friction in time-to-market.
FAQ — Technical Insights for Formulators
What are the main trends for the Consumer Health OTC market in 2026?
The sector’s growth is driven by proactive self-care, with emphasis on the categories of VMS (Vitamins, Minerals and Supplements), digestive health, and the intersection between pharmaceuticals and skin health. Innovation is now guided by convenience (new formats) and the demand for Clean Label.
How does the choice of excipients impact innovation in OTC and VMS formulations?
High-performance excipients are strategic to ensure the stability of sensitive active ingredients, improve solubilization, and enable new delivery formats (such as gums or films). In addition, the use of high-purity ingredients facilitates compliance with the Clean Label trend, reducing the need for complex additives.
How does the OXIPURITY® line assist in the development of consumer health products?
The OXIPURITY® line offers excipients developed to meet the requirements of pharmaceutical and nutritional standards. These ingredients are important for consistent performance and are accompanied by technical and regulatory documentation compliant with references such as ANVISA, FDA, and EMA, supporting development processes and facilitating the regulatory advancement of OTC products.
How to adapt traditional formulations to the new demands of "Clean Label"?
Adaptation requires the selection of ingredients with a higher degree of purity and multifunctionality. By using solutions like those from Indovinya, formulators simplify the ingredient list while maintaining technical performance and safety, essential aspects for the Consumer Health consumer.
What solutions does Indovinya offer for the digestive health and immunity segment?
We offer a complete portfolio of excipients and technical additives that guarantee the protection of probiotics and vitamins against handling, ensuring that the final product maintains its potency and effectiveness throughout its shelf life.
How can I accelerate time-to-market for new OTC formats?
The key is choosing pre-qualified excipients with full documentation (CoA and dossiers). This reduces the time spent on stability testing and regulatory hurdles.
What is the impact of "Clean Label" on OTC manufacturing?
It requires a shift toward higher-purity ingredients that perform multiple functions, reducing the total number of additives in the formula.
Indovinya: Your Strategic Partner in Consumer Health
At Indovinya, we bridge the gap between consumer trends and pharmaceutical rigor. Our portfolio of excipients and ingredients is designed to help you navigate the complexities of the modern OTC market.
We provide more than just ingredients; we provide regulatory confidence and technical partnership. Whether you are formulating a new supplement or optimizing a classic OTC treatment, our solutions ensure your product is ready for the “next phase” of health.
Talk to our specialists and discover how we can support your next innovation in Consumer Health.
References:
IQVIA – Consumer Health’s Next Phase (2026).
Indovinya Internal Technical Studies on OXIPURITY® Performance.
